On June 25, 2019, Zhang, Xingxian published a patent.Reference of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate The title of the patent was Compound for targeted ubiquitination degradation of EGFR protein and its pharmaceutical composition and application. And the patent contained the following:
Title compounds I [wherein A = (CH2CH2O)nCH2 or (CH)n, n is 1 to 6; B = (CH2)m, m is 1 or 2], and their pharmaceutically acceptable salts thereof, were prepared as EGFR inhibitors, useful in the treatment of cancer (breast cancer, colon cancer, prostate cancer, etc.). Thus, the invention compound I [A = (CH2)3; B = CH2] was prepared and gave PC9 inhibition IC50 value of 0.8444 μM. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Reference of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate
The Article related to heteroaryl antitumor egfr inhibitor preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Reference of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics